NasdaqGS:VRTXBiotechs
Vertex Pharmaceuticals (VRTX) On Guidance Upgrade And Pipeline Growth Narrative】【。
Earnings guidance change and new partnership set the context for Vertex Pharmaceuticals stock
Vertex Pharmaceuticals (VRTX) recently reported second quarter 2026 results, updated its full year revenue guidance, and announced a new collaboration with AbCellera Biologics on multispecific T cell engagers for autoimmune diseases.
See our latest analysis for Vertex Pharmaceuticals.
Vertex Pharmaceuticals has seen steady positive momentum, with the share price at US$496.07 and a 90 day share price...